Median Technologies has initiated a €40 million capital increase, potentially rising to €50 million, aimed at enhancing the commercial rollout of its AI-driven eyonis LCS lung cancer screening platform in the U.S. and Europe, while also expanding its capabilities to address additional cancer types.
The capital increase will occur via a public offering of ordinary shares, with a reserved offering for guarantors amounting to €10 million contingent on full subscription. Median Technologies has already secured €30 million in commitments, covering 75% of the public offering. The set subscription price is €5 per share, with the funds primarily allocated for the eyonis LCS commercial launch and the development of new AI-based medical software for other cancer indications, ensuring operational support until mid-2028.
The eyonis LCS platform gained FDA 510(k) clearance in February 2026, demonstrating impressive clinical metrics including 93.3% sensitivity and 99.9% negative predictive value. The U.S. lung cancer screening market is estimated to exceed $9 billion, fueled by a significant number of eligible patients and favorable reimbursement frameworks.
Median Technologies is pursuing several key partnerships and strategies to facilitate the platform's market entry. A CE marking decision for eyonis LCS is anticipated soon, which would further support its deployment across Europe. The company also aims to expand the eyonis platform to cover additional cancer types, leveraging advancements in AI and medical imaging to shift the focus from late to early-stage diagnosis.
This strategic funding initiative underscores Median Technologies' commitment to transforming cancer diagnostics through AI, positioning itself at the forefront of early detection and intervention in oncology. The emphasis on early diagnosis could significantly impact patient outcomes and reshape healthcare systems focused on late-stage treatments.